Cytokinetics (CYTK) Is Down 6.2% After Positive Phase 3 Aficamten Data In Non-Obstructive HCM - Has The Bull Case Changed?

Cytokinetics (NASDAQ:CYTK) reported late-stage trial results for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), meeting primary goals of improving symptoms and quality of life. The study showed 53% of patients on aficamten improved in key areas vs. 13% on placebo, but lacked significant structural or cardiovascular benefits. The company plans a US marketing application in Q4 2026. Analysts forecast peak sales of over $5 billion for Myqorzo, but investors expressed concerns over

Cytokinetics (CYTK) presented additional results from ACACIA-HCM and MAPLE-HCM studies at the European Society of Cardiology Congress 2026, showing aficamten's benefits in non-obstructive HCM (nHCM) and superiority over metoprolol in obstructive HCM (oHCM). CYTK plans to submit an sNDA for aficamten in nHCM in Q4 2026. Myqorzo (aficamten) faces competition from Bristol Myers Squibb's (BMY) Camzyos and Edgewise Therapeutics' (EWTX) EDG-7500. CYTK shares are up 12.4% YTD, trading at 26.6X forward

Cytokinetics (NASDAQ:CYTK) reported positive results from its ACACIA-HCM Phase 3 trial of aficamten for non-obstructive hypertrophic cardiomyopathy, meeting primary endpoints and showing improvements in symptoms and exercise performance. The drug showed benefits in five key areas, but some safety concerns were noted. Cytokinetics plans to file for FDA approval in Q4 2026. Shares fell 3.19% to $69.79.

Moderna and Merck's mRNA vaccine for melanoma showed promising results, potentially reducing stigma around mRNA vaccines. At the European Society of Cardiology Congress, Novartis' drug Pacibekitug showed promise in reducing inflammation, AstraZeneca's experimental drug failed in a study, and Cytokinetics' aficamten showed positive results for non-obstructive hypertrophic cardiomyopathy. Type 1 diabetes cases are projected to rise significantly by 2049.

Cytokinetics reported $25.3M in MYQORZO sales for Q2, with 700+ healthcare providers prescribing it. Armistice Capital increased its stake by 57% to 1.2M shares. The company plans to submit a supplemental drug application for non-obstructive HCM in Q4 2026. Total revenue fell to $28.6M from $66.8M YoY due to lower collaboration payments. Cytokinetics ended Q2 with $1.7B in cash and investments.

Cytokinetics (CYTK) shares fell 7.7% following the release of full Phase 3 ACACIA-HCM trial data for aficamten, which met primary endpoints but showed treatment interruptions and adverse events. The next milestone is a 2026 FDA filing. Investors may have already priced in positive topline results from May.